The First Thrombotic Event in Purely Obstetric Antiphospholipid Syndrome Patients and in Antiphospholipid Antibody Carriers: Comparison of Incidence and Characteristics

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2020 Sep 4

PMID 32880711

Citations 2

Authors

Marta Tonello

Antonia Calligaro

Maria Favaro

Teresa Del Ross

Paola Veronese

Elisa Salvan

Maria Teresa Gervasi

Amelia Ruffatti

Affiliations

Soon will be listed here.

Abstract

Purpose: The long-term risk of thrombosis after pregnancy in women with purely obstetric antiphospholipid syndrome (OAPS) is not well defined. The current study's primary outcome was to evaluate the incidence and characteristics of the first thrombotic event in OAPS, identifying the risk factors for thrombosis in OAPS was its secondary one.

Methods: Patients with purely OAPS were consecutively enrolled between September 1999 and September 2019. Subjects without a history of pregnancy morbidity or thrombosis but with persistent positivity for one or more antiphospholipid antibodies (aPL carriers) made up the control group. The study groups included 94 OAPS patients and 124 aPL carriers who were matched for clinical and laboratory parameters.

Results: An event rate of 0.49/100 patient years was registered in OAPS patients during a mean follow-up of 8.7 years ± 5.5 SD. Kaplan-Meier survival analysis revealed that the cumulative incidence of thromboembolic events was not significantly different in OAPS patients vs aPL carriers. Arterial thrombosis and cerebrovascular events were the more frequent types of vascular involvement in the two groups. As far as risk factors for thrombosis were concerned, the presence of lupus anticoagulant significantly prevailed in both thrombotic OAPS patients and thrombotic aPL carriers with respect to purely OAPS patients and aPL carriers who did not develop thrombosis (p = 0.01 and p = 0.00, respectively).

Conclusion: Just as for aPL carriers, closer monitoring and possibly, a pharmacological prophylaxis should be reserved for OAPS patients at highest risk of developing the first thrombotic event.

Citing Articles

Risk factors of first thrombosis in obstetric antiphospholipid syndrome.

Luo L, Cai Q, Liu X, Hou Y, Li C Lupus Sci Med. 2024; 11(1).

PMID: 38176700 PMC: 10773425. DOI: 10.1136/lupus-2023-001044.

Thrombophilia testing: A British Society for Haematology guideline.

Arachchillage D, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M Br J Haematol. 2022; 198(3):443-458.

PMID: 35645034 PMC: 9542828. DOI: 10.1111/bjh.18239.

References

Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

Lassere M, Empson M . Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials. Thromb Res. 2004; 114(5-6):419-26. DOI: 10.1016/j.thromres.2004.08.006. View

Ruffatti A, Tonello M, Hoxha A, Sciascia S, Cuadrado M, Latino J . Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thromb Haemost. 2018; 118(4):639-646. DOI: 10.1055/s-0038-1632388. View

Erkan D, Merrill J, Yazici Y, Sammaritano L, Buyon J, Lockshin M . High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001; 44(6):1466-7. DOI: 10.1002/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C. View

Tincani A, Taglietti M, Biasini C, Frassi M, Gorla R, Balestrieri G . Thromboembolic events after fetal loss in patients with antiphospholipid syndrome: comment on the article by Erkan et al. Arthritis Rheum. 2002; 46(4):1126-7; author reply 1127. DOI: 10.1002/art.10165. View

Quenby S, Farquharson R, Dawood F, Hughes A, Topping J . Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reprod. 2005; 20(6):1729-32. DOI: 10.1093/humrep/deh844. View

Lefevre G, Lambert M, Bacri J, Dubucquoi S, Quemeneur T, Caron C . Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. Lupus. 2011; 20(8):861-5. DOI: 10.1177/0961203310397080. View

Gris J, Chauleur C, Molinari N, Mares P, Fabbro-Peray P, Quere I . Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011; 106(6):1053-61. DOI: 10.1160/TH11-05-0340. View

Martinez-Zamora M, Peralta S, Creus M, Tassies D, Reverter J, Espinosa G . Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. Ann Rheum Dis. 2011; 71(1):61-6. DOI: 10.1136/ard.2011.153817. View

10.

de Jesus G, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A . Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG. 2018; 126(5):656-661. PMC: 7382947. DOI: 10.1111/1471-0528.15469. View

11.

Ruffatti A, Olivieri S, Tonello M, Bortolati M, Bison E, Salvan E . Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost. 2008; 6(10):1693-6. DOI: 10.1111/j.1538-7836.2008.03121.x. View

12.

Pengo V, Tripodi A, Reber G, Rand J, Ortel T, Galli M . Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009; 7(10):1737-40. DOI: 10.1111/j.1538-7836.2009.03555.x. View

13.

Ruffatti A, Tonello M, Visentin M, Bontadi A, Hoxha A, De Carolis S . Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford). 2011; 50(9):1684-9. DOI: 10.1093/rheumatology/ker139. View

14.

Lockshin M, Kim M, Laskin C, Guerra M, Branch D, Merrill J . Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012; 64(7):2311-8. PMC: 3357451. DOI: 10.1002/art.34402. View

15.

Barbhaiya M, Erkan D . Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?. Curr Rheumatol Rep. 2010; 13(1):59-69. DOI: 10.1007/s11926-010-0149-3. View

16.

Ruffatti A, Ross T, Ciprian M, Bertero M, Sciascia S, Salvatore S . Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011; 70(6):1083-6. DOI: 10.1136/ard.2010.142042. View

17.

Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F . Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011; 118(17):4714-8. DOI: 10.1182/blood-2011-03-340232. View

18.

Urbanus R, Siegerink B, Roest M, Rosendaal F, de Groot P, Algra A . Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009; 8(11):998-1005. DOI: 10.1016/S1474-4422(09)70239-X. View